Home  /  Resource Library  /  Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells Following Autologous HSCT in Patients with B-NHL

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells Following Autologous HSCT in Patients with B-NHL

Results of a study investigating dual CD22 and CD18 CAR T therapies for treatment of relapsed aggressive B-cell lymphomas.